Phase I trial improvement: a question of patient selection, trial design, or both?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Smartphone measurements of physical activity and fitness are associated with early trial discontinuation of patients in (hemato)oncology phase I/II clinical trials.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
   Trial
2. Trends of Phase I Clinical Trials in the Latest Ten Years across Five European Countries.International journal of environmental research and public health · 2022
   Article
3. Mitochondrial Replacement Therapy: Halachic Considerations for Enrolling in an Experimental Clinical Trial.Rambam Maimonides medical journal · 2015
   Article

Corrections and comments

• Comment on
  Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.2014

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as